# Study to ONO-4538 in Patients With Rhabdoid Tumor

> **NCT06622941** · PHASE2 · RECRUITING · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 23 (estimated)

## Conditions studied

- Rhabdoid Tumor

## Interventions

- **DRUG:** ONO-4538

## Key facts

- **NCT ID:** NCT06622941
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2029-01-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06622941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06622941, "Study to ONO-4538 in Patients With Rhabdoid Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06622941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*